Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Granulin, also known as progranulin (PGRN), is a multifunctional protein involved in various biological processes including lysosomal function, neuroinflammation, and neuronal survival. It is the precursor to several granulin motifs. Mutations in the GRN gene, which encodes progranulin, are a significant cause of hereditary Frontotemporal Dementia (FTD) due to reduced progranulin levels. Therapeutically, granulin or its derived peptides are being investigated for their potential to restore progranulin levels in FTD or for applications like wound healing. Conversely, elevated progranulin levels are associated with increased malignancy in tumors and are being studied as a biomarker for conditions such as prediabetes and diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Granulin.